Life Sciences in Focus: IP, Regulation & Compliance
LSX Investor Perception Survey 2019

In this extract from the LSX Investor Perception Survey 2019, investors share their views on the UK’s decision to exit the EU. We also examine the sway that IP and other factors have over respondents’ investment decisions. The 3rd annual LSX Investor Perception Survey tracks sentiment, aims, and preferences among the life science investment community. 

Download the white paper to:
  • Find out the importance investors attach to intellectual property and the criteria they prioritise when considering investment opportunities.
  • Better understand how Brexit is impacting respondents’ investment strategies.
  • Learn about the implications of the UK exiting the EU that are causing most concern among the investment community.
  • Read commentary and insights from Tim Sarson, Partner and Brexit Lead for Life Sciences at KPMG, and Simon Turner, Managing Partner at Alacrita.

Enter your details here to receive the white paper

Formerly Known as Blog Resize

LSX (formerly Biotech and Money) is an influential community of senior life science decision makers. Through our impactful events, powerful thought leadership content and unique networking opportunities, we exist to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.